LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Christie Hospital NHS Foundation Trust
Mánchester, Reino UnidoPublicaciones en colaboración con investigadores/as de Christie Hospital NHS Foundation Trust (29)
2024
-
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816
2023
-
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
Journal of Hematology and Oncology, Vol. 16, Núm. 1
-
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
The Lancet, Vol. 401, Núm. 10378, pp. 733-746
2022
-
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1415-1427
-
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Annals of Oncology, Vol. 33, Núm. 5, pp. 466-487
-
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 12, pp. 1301-1311
-
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial
ESMO Open, Vol. 7, Núm. 2
-
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
Nature medicine, Vol. 28, Núm. 4, pp. 752-765
2021
-
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial
Journal of Thoracic Oncology, Vol. 16, Núm. 5, pp. 860-867
2020
-
Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts
Radiotherapy and Oncology, Vol. 149, pp. 84-88
2019
-
Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2109-2119
-
Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts
Radiotherapy and Oncology, Vol. 133, pp. 163-166
-
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
The Lancet Oncology, Vol. 20, Núm. 8, pp. 1109-1123
2018
-
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer
Journal of Thoracic Oncology, Vol. 13, Núm. 2, pp. 165-183
-
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study
Journal of Thoracic Oncology, Vol. 13, Núm. 2, pp. 228-236
-
Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small-Cell Lung Cancer
Clinical Lung Cancer, Vol. 19, Núm. 2, pp. 130-138.e2
-
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies
Clinical Lung Cancer, Vol. 19, Núm. 4, pp. 331-339
-
Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis
Thrombosis Research, Vol. 167, pp. 50-56
2016
-
1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)
Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S153
-
Clinicopathologic features of advanced squamous NSCLC
Journal of Thoracic Oncology, Vol. 11, Núm. 9, pp. 1411-1422